JP2020506693A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506693A5 JP2020506693A5 JP2019540076A JP2019540076A JP2020506693A5 JP 2020506693 A5 JP2020506693 A5 JP 2020506693A5 JP 2019540076 A JP2019540076 A JP 2019540076A JP 2019540076 A JP2019540076 A JP 2019540076A JP 2020506693 A5 JP2020506693 A5 JP 2020506693A5
- Authority
- JP
- Japan
- Prior art keywords
- ace2
- variant
- amino acid
- acid sequence
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (18)
- 配列番号3又は配列番号4に示されるアミノ酸配列を含むアンジオテンシン変換酵素2の変異体(ACE2)の変異体であって、該変異体はACE2活性を有し、分子量は60kDaから71kDaの範囲であり、糸球体濾過を介した送達を可能にする、ACE2の変異体。
- ACE2の変異体が、全長ACE2(配列番号1)と比較して、N末端欠失、C末端欠失、又はその両方をさらに含む、請求項1に記載のACE2の変異体。
- 欠失が全長ACE2に存在するグリコシル化部位を除去する、請求項2に記載のACE2の変異体。
- ACE2の変異体が、AngII(1−8)をAng(1−7)に変換するために、全長ACE2(配列番号1)よりも高いACE2活性を有する、請求項1に記載のACE2の変異体。
- ACE2の変異体が、少なくとも1週間の血漿中半減期を有する、請求項1に記載のACE2の変異体。
- 血漿中のACE2の変異体の半減期を増加させる異種アミノ酸配列に融合した請求項1に記載のACE2の変異体を含む融合タンパク質。
- 融合タンパク質が、少なくとも1週間の血漿中半減期を有する、請求項6に記載の融合タンパク質。
- 異種アミノ酸配列が、(i)融合ポリペプチドの二量体化を防ぐヒンジ領域を欠損している抗体のFc部分のアミノ酸配列又はその断片;(ii)ヒト血清アルブミンのドメインIIIのアミノ酸配列又はその断片;及び(iii)連鎖球菌プロテインGのC末端アルブミン結合ドメイン3(ABD3)のアミノ酸配列からなる群から選択されるアミノ酸配列を含む、請求項6に記載の融合タンパク質。
- ACE2の変異体と異種アミノ酸配列との間にリンカーアミノ酸配列をさらに含み、リンカー配列がグリシン及びセリンから選択される5〜15個のアミノ酸を含む、請求項6に記載の融合タンパク質。
- N末端又はC末端ヒスチジンタグをさらに含む、請求項6に記載の融合タンパク質。
- ポリエチレングリコールポリマーに結合した請求項1に記載のACE2の変異体を含む結合体。
- ナノ粒子に結合した請求項1に記載のACE2の変異体を含む結合体。
- ポリエチレングリコールポリマー又はナノ粒子に結合した請求項1に記載のACE2の変異体を含む結合体であって、少なくとも1週間の血漿中半減期を有する結合体。
- (i)請求項1に記載のACE2の変異体;及び(ii)適切な医薬用担体を含む医薬組成物。
- 請求項14に記載の医薬組成物を対象に投与することを含む、それを必要とする対象においてAngII(1−8)レベルを減少させる及び/又はAng(1−7)レベルを増加させる方法。
- 対象が、糖尿病性腎疾患、急性腎不全、慢性腎疾患、糸球体腎炎、腎動脈狭窄、特発性肺線維症、肝硬変患者における肝線維症、大動脈瘤、心臓の線維化とリモデリング、左心室肥大、及び急性脳卒中からなる群から選択される状態を有する、請求項15に記載の方法。
- 医薬組成物が静脈内投与又は皮下投与により投与される、請求項15に記載の方法。
- 医薬組成物が肺投与される、請求項15に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023127196A JP2023133564A (ja) | 2017-01-24 | 2023-08-03 | アンジオテンシン変換酵素2(ace2)の活性な低分子量変異体 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762449857P | 2017-01-24 | 2017-01-24 | |
US62/449,857 | 2017-01-24 | ||
PCT/US2018/014991 WO2018140456A1 (en) | 2017-01-24 | 2018-01-24 | Active low molecular weight variants of angiotensin converting enzyme 2 (ace2) |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023127196A Division JP2023133564A (ja) | 2017-01-24 | 2023-08-03 | アンジオテンシン変換酵素2(ace2)の活性な低分子量変異体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020506693A JP2020506693A (ja) | 2020-03-05 |
JP2020506693A5 true JP2020506693A5 (ja) | 2021-03-11 |
JP7332157B2 JP7332157B2 (ja) | 2023-08-23 |
Family
ID=62979214
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019540076A Active JP7332157B2 (ja) | 2017-01-24 | 2018-01-24 | アンジオテンシン変換酵素2(ace2)の活性な低分子量変異体 |
JP2023127196A Pending JP2023133564A (ja) | 2017-01-24 | 2023-08-03 | アンジオテンシン変換酵素2(ace2)の活性な低分子量変異体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023127196A Pending JP2023133564A (ja) | 2017-01-24 | 2023-08-03 | アンジオテンシン変換酵素2(ace2)の活性な低分子量変異体 |
Country Status (4)
Country | Link |
---|---|
US (3) | US10443049B2 (ja) |
EP (1) | EP3574094A4 (ja) |
JP (2) | JP7332157B2 (ja) |
WO (1) | WO2018140456A1 (ja) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3574094A4 (en) | 2017-01-24 | 2020-11-11 | Northwestern University | LOW MOLECULAR WEIGHT ACTIVE VARIANTS OF ANGIOTENSIN II CONVERTING ENZYME (ECA II) |
AU2018376565A1 (en) | 2017-11-29 | 2020-05-28 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation |
JP7340372B2 (ja) * | 2019-07-11 | 2023-09-07 | 浜松ホトニクス株式会社 | 光活性化アデニル酸シクラーゼ |
US11518788B2 (en) * | 2020-07-10 | 2022-12-06 | Avirus, Inc. | Methods and compositions for treating and preventing viral infection |
JP2023511125A (ja) * | 2020-01-23 | 2023-03-16 | アヴァイルス,インコーポレイテッド | ウイルス感染を治療及び予防するための方法及び組成物 |
US20210236583A1 (en) * | 2020-02-03 | 2021-08-05 | Yuntao Wu | Targeting the renin-angiotensin system for treatment of environment-and pathogen-induced lung injury |
CN111474363A (zh) * | 2020-02-22 | 2020-07-31 | 安徽华培生物科技有限公司 | 一种新型冠状病毒检测方法 |
WO2021174107A2 (en) * | 2020-02-26 | 2021-09-02 | Northwestern University | Soluble ace2 variants and uses therefor |
US20230348880A1 (en) * | 2020-02-27 | 2023-11-02 | National Institute Of Biological Sciences, Beijing | Soluble ace2 and fusion protein, and applications thereof |
WO2021170113A1 (zh) * | 2020-02-29 | 2021-09-02 | 南京金斯瑞生物科技有限公司 | ACE-2-Fc融合蛋白治疗冠状病毒的方法 |
EP4118109A1 (en) | 2020-03-11 | 2023-01-18 | NantCell, Inc. | Proteinaceous therapeutics |
US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
CN116057176A (zh) * | 2020-03-21 | 2023-05-02 | 赖瑞克斯生物科技公司 | Ace2和补体途径的双特异性和三特异性功能分子及其用途 |
WO2021195009A1 (en) * | 2020-03-23 | 2021-09-30 | Sapience Therapeutics, Inc. | Peptide antagonists of ace2-binding proteins |
CN113444710A (zh) * | 2020-03-25 | 2021-09-28 | 上海英脉德医疗科技有限公司 | ACE2-Fc融合蛋白及其用途 |
WO2021202456A1 (en) * | 2020-03-30 | 2021-10-07 | The Wistar Institute Of Anatomy And Biology | Synthetic soluble receptor mimics and methods of use for treatment of covid-19 |
WO2021197501A1 (zh) * | 2020-04-02 | 2021-10-07 | 创观(苏州)生物科技有限公司 | 病毒不易感动物 |
US20230203466A1 (en) * | 2020-04-03 | 2023-06-29 | Medgenome Inc. | Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment |
WO2021203098A2 (en) * | 2020-04-03 | 2021-10-07 | The University Of North Carolina At Chapel Hill | Binding proteins useful against ace2-targeted viruses |
US20230158125A1 (en) * | 2020-04-20 | 2023-05-25 | Sorrento Therapeutics, Inc. | Pulmonary Administration of ACE2 Polypeptides |
WO2021237239A1 (en) * | 2020-05-18 | 2021-11-25 | Northwestern University | Active low molecular weight variant of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye |
US11773385B2 (en) * | 2020-05-19 | 2023-10-03 | Children's Medical Center Corporation | High-affinity human ACE2 construct for use in diagnosing and treating coronaviruses |
WO2021247675A1 (en) * | 2020-06-02 | 2021-12-09 | Ngm Biopharmaceuticals, Inc. | Coronavirus-binding agents and uses thereof |
DE102020207224A1 (de) | 2020-06-09 | 2021-12-09 | Christoph Karle | Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon |
WO2022008642A1 (en) | 2020-07-08 | 2022-01-13 | Apeiron Biologics Ag | Treatment of sars-cov-2 infection with a combination of targets |
WO2022012688A1 (en) * | 2020-07-17 | 2022-01-20 | Shenzhen Bay Laboratory | Ace2-ig fusion variants |
KR102492081B1 (ko) * | 2020-07-28 | 2023-01-26 | 재단법인대구경북과학기술원 | 코로나바이러스 감염증 covid-19 치료용 펩타이드 및 이의 용도 |
US20220041660A1 (en) * | 2020-08-06 | 2022-02-10 | University Of Delaware | Compositions and methods for sequestering viral particles in respiratory tract |
WO2022035998A1 (en) * | 2020-08-11 | 2022-02-17 | City Of Hope | Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells |
US20230365956A1 (en) * | 2020-10-01 | 2023-11-16 | Systimmune, Inc. | Recombinant ace2-fc fusion molecules and methods of making and using thereof |
WO2022075667A1 (ko) * | 2020-10-05 | 2022-04-14 | 한양대학교 산학협력단 | 안정화된 ace2 변이체, 이를 이용한 ace2-fc 융합단백질 및 covid-19 예방 또는 치료용 약학 조성물 |
WO2022082217A1 (en) * | 2020-10-16 | 2022-04-21 | Eureka Therapeutics, Inc. | Compositions for preventing or treating viral and other microbial infections |
EP4249499A1 (en) * | 2020-11-20 | 2023-09-27 | Daegu Gyeongbuk Institute Of Science and Technology | Coronavirus infectious disease covid-19 therapeutic proteins ctp alpha, ctp beta, ctp gamma, ctp delta, and uses thereof |
MX2023005878A (es) | 2020-11-23 | 2023-06-05 | Genentech Inc | Metodos para modular las interacciones de la superficie de la celula huesped con sars-cov-2. |
WO2022119380A1 (ko) * | 2020-12-03 | 2022-06-09 | 주식회사 유틸렉스 | 신규한 ace2 변이체 및 그의 이용 |
EP4011387A1 (en) * | 2020-12-11 | 2022-06-15 | IMBA-Institut für Molekulare Biotechnologie GmbH | Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2 |
WO2022159433A1 (en) | 2021-01-20 | 2022-07-28 | Singh Biotechnology, Llc | Therapeutics directed against coronavirus |
CN117321196A (zh) * | 2021-01-26 | 2023-12-29 | 加拿大国家研究委员会 | Ace2-受体胞外域融合分子及其用途 |
WO2022165245A1 (en) * | 2021-01-29 | 2022-08-04 | The Trustees Of The University Of Pennsylvania | Compositions and method of use of mutant ace2 decoy variants |
JP2023537546A (ja) * | 2021-02-10 | 2023-09-04 | シーチュアン バイリ ファーマスーティカル シーオー. エルティーディー. | 組換えace2-fc融合分子、その製造方法及びその使用 |
WO2022207918A1 (en) | 2021-04-02 | 2022-10-06 | Apeiron Biologics Ag | COVID-19 Therapy |
WO2022246041A2 (en) * | 2021-05-20 | 2022-11-24 | Achelois Biopharma, Inc. | Compositions and methods for multivalent surface display on enveloped particles |
CN113324933B (zh) * | 2021-06-01 | 2022-07-26 | 浙江大学 | 一种检测血管紧张素转换酶的方法及其应用 |
WO2022271863A1 (en) * | 2021-06-23 | 2022-12-29 | Chan Zuckerberg Biohub, Inc. | Coronavirus neutralizing compositions and associated methods |
WO2023108040A2 (en) * | 2021-12-09 | 2023-06-15 | Gliknik Inc. | Ace2-fc fusion proteins and methods of use |
EP4335870A1 (en) | 2022-09-06 | 2024-03-13 | NantCell, Inc. | Peptide therapeutics against sars-cov-2 spike protein |
DE202023100085U1 (de) | 2023-01-09 | 2023-02-03 | Sundararajan Gothandam | Eine doppelte Blockade des Renin-Angiotensin-Systems zur Verringerung der frühen Veränderungen der diabetischen Retinopathie und Nephropathie |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4540930A (en) | 1983-09-12 | 1985-09-10 | Wisconsin Alumni Research Foundation | Plywheel-powered mobile X-ray apparatus |
US5124154A (en) | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
US6610497B1 (en) | 1997-12-11 | 2003-08-26 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
WO2002061131A2 (en) | 2000-12-04 | 2002-08-08 | Bristol-Myers Squibb Company | Human single nucleotide polymorphisms |
AT506258A1 (de) | 2007-12-18 | 2009-07-15 | Apeiron Biolog Forschungs Und | Behandlung inflammatorischer krankheiten |
KR20120092611A (ko) * | 2009-09-30 | 2012-08-21 | 글락소 그룹 리미티드 | 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트 |
WO2013119870A1 (en) * | 2012-02-10 | 2013-08-15 | Tarix Pharmaceuticals Ltd. | Compositions and methods for treatment of peripheral vascular disease |
MX355041B (es) * | 2012-05-25 | 2018-03-28 | Janssen Biotech Inc | Dominios de union a albumina consenso no naturales. |
CA2897251C (en) * | 2013-01-14 | 2022-07-12 | Apeiron Biologics Ag | Modified ace2 polypeptides |
WO2015058214A1 (en) | 2013-10-18 | 2015-04-23 | Trustees Of The University Of Pennsylvania | Oral delivery of angiotensin converting enzyme 2 (ace2) or angiotensin-(1-7) bioencapsulated in plant cells |
EP3574094A4 (en) | 2017-01-24 | 2020-11-11 | Northwestern University | LOW MOLECULAR WEIGHT ACTIVE VARIANTS OF ANGIOTENSIN II CONVERTING ENZYME (ECA II) |
WO2021174107A2 (en) | 2020-02-26 | 2021-09-02 | Northwestern University | Soluble ace2 variants and uses therefor |
WO2021237239A1 (en) | 2020-05-18 | 2021-11-25 | Northwestern University | Active low molecular weight variant of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye |
-
2018
- 2018-01-24 EP EP18745455.8A patent/EP3574094A4/en active Pending
- 2018-01-24 WO PCT/US2018/014991 patent/WO2018140456A1/en unknown
- 2018-01-24 JP JP2019540076A patent/JP7332157B2/ja active Active
- 2018-01-24 US US15/878,823 patent/US10443049B2/en active Active
-
2019
- 2019-10-14 US US16/601,545 patent/US11078471B2/en active Active
-
2021
- 2021-08-02 US US17/391,680 patent/US11891638B2/en active Active
-
2023
- 2023-08-03 JP JP2023127196A patent/JP2023133564A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020506693A5 (ja) | ||
US11535659B2 (en) | Engineered polypeptides having enhanced duration of action | |
JP4659068B2 (ja) | Ob融合タンパク質組成物および方法 | |
US7112659B2 (en) | OB fusion protein compositions and methods | |
US9879063B2 (en) | Engineered polypeptides having enhanced duration of action and reduced immunogenicity | |
US8420098B2 (en) | Fibronectin based scaffold domain proteins that bind to PCSK9 | |
JP2016511752A5 (ja) | ||
JP2019085420A (ja) | エラスチン様ペプチドを含む治療剤 | |
TW202225183A (zh) | Gdf15融合蛋白及其用途 | |
JP5907970B2 (ja) | インターロイキン−22のウイルス性肝炎の治療における応用 | |
JP2008521426A5 (ja) | ||
JP2017531613A5 (ja) | ||
JP2008535800A5 (ja) | ||
JP2010202664A5 (ja) | ||
AU2020343512A1 (en) | Therapeutic fusion proteins | |
RU2018118836A (ru) | Препарат фактора свёртывания крови viii | |
JP2018529760A (ja) | 長半減期凝固複合体と関連する方法及び組成物 | |
RU2021136703A (ru) | Новый модифицированный слитый белок fc-фрагмента иммуноглобулина и его применение | |
AU2016371021A1 (en) | Ameliorating systemic sclerosis with death receptor agonists |